DALLAS / Apr 01, 2024 / Business Wire / Tenet Healthcare Corporation (NYSE: THC) today announced that it has completed the sale of six hospitals and related operations in California consistent with previously disclosed terms.
Tenet completed the sale of its four Orange County and Los Angeles County hospitals and related operations to UCI Health – consistent with the approval of the University of California Board of Regents. The completed transaction includes Fountain Valley Regional Hospital, Lakewood Regional Medical Center, Los Alamitos Medical Center, Placentia-Linda Hospital, and related operations.
Tenet completed the sale of its two San Luis Obispo hospitals and related operations to Adventist Health. The completed transaction includes Sierra Vista Regional Medical Center, Twin Cities Community Hospital, and related operations.
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.
Last Trade: | US$128.89 |
Daily Change: | -0.83 -0.64 |
Daily Volume: | 24,879 |
Market Cap: | US$12.260B |
October 29, 2024 July 24, 2024 April 30, 2024 February 08, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB